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INTRODUC11ON FOR ANNUAL REPORT 1992
During 1992, the Cancèr Committee continued to function as a multidisciplinary committee by overseeing and monitoring the Oncology Program
at St. Luke’s Medical Center. A Task Force for programmatic development in
the area of breast cancer and a Tumor Board Task Force for improvement of
our weekly tumor conferences were formed. We supported obtaining a
clinical research coordinator for the Oncology Program and a clinical nurse
specialist whose expertise was prevention and early detection of cancer and
pain management.
Monitoring activities of the committee included reporting of the short-term
and long-term Patient Care Evaluations through the American College of
Surgeons on cancer of the pancreas and cancer of the prostate. In-house
studies were performed on prostate cancer and multiple myeloma with all
results being discussed at Cancer Committee meetings. In addition, the
committee oversaw the pilot program for Beta Indicators under the direction
of the Joint Commission on Accreditation of Healthcare Organizations
(JCAHO) within medical records.

Marcia J.S.
Richards, M.D.

Educational efforts for the medical staff included a Security Bank Cancer
Lectureship Series and a Surgical Oncology Roundtable Series. Due to the
continued support of the Vince Lombardi Golf Classic, resources were made
available for public education forums on prostate, breast, colon, skin, ovarian
and cervical malignancies as well as screening and prevention programs. The
1 992 Golf Classic and the second Award of Excellence Dinner recognizing
Bob Hope were both resounding resources.
Efforts in conjunction with the American Cancer Society included sponsoring
a Bike-a-Thon and an inspirational television program on Profiles in Survival.
Much as the Cancer Committee monitors, oversees, and evaluates the program
within the institution, the American College of Surgeons tACoS) does the same
to evaluate the efforts of the Cancer Committee in performing their assigned
roles. We are pleased to report that we were site visited and received an
unqualified three year accreditation.
The Oncology Program at St. Luke’s Medical Center has again experienced a
year of growth in patient services, an increase in patient numbers, new
programmatic development in the area of oncology, and continued cancer
education of the medical staff and community.
Marcia J.S. Richards, MD
Chairperson, Cancer Committee
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EPIDEMIOLOGY OF COLON CANCER
Colon cancer remains difficult to treat largely due to the inability to
establish an early diagnosis. This disease is responsible for approximately
60,000 deaths per year, and 150,000 new cases are diagnosed every year.
Approximately 5 % of all Americans will develop colon cancer in their
lifetime.
Several factors may be associated with the development of colon cancer.
Incidence appears to increase with age, doubling with each decade after age
50. Colon polyps, which are benign growths in the lining of the colon, are
well accepted forerunners to colon cancer. Certain types of polyps called
adenomas appear to slowly progress to colon cancer. As with colon cancer,
the risk of polyps increases with age.

Thomas G.
Malloy, MD

Genetic factors may also be important. Individuals with first degree relatives
having colon cancer and/or polyps have two to four times the increased risk.
Rare, hereditary polyp syndromes, will all evolve into colon carcinoma,
unless they are treated.

According to Cancer Facts &
Figures 1987:
-

The incidence ofcolon cancer tends to
increase with age. The majority of patients
are thought to be diagnosed after the age of
40 with approximately 94% ofall cases
occurring after the age of SO. These figures
appear to be consistent with those here at
St. Luke’s Medical Center where 92.2 % of the
patients diagnosed in 1 987 and 94.9% of the
patients diagnosed in 1 992 were over 50 years
old. A screening program is more likely to be
successful ifa subgroup ofpatients at high
risk developing the disease can be identified.
Since the graphs show a majority ofpatients
being diagnosed over the age of 50, a target
group can be identified. Screening for this
group could make a difference in survival if
the patients are diagnosed earlier.

Other bowel disorders also carry an increased risk of colon cancer. A
patient with chronic inflammatory bowel disease, especially ulcerative colitis,
has a significantly increased risk of colon cancer compared to the normal
population. Also, individuals with a prior history of colon malignancy have
increased likelihood of a second episode.
Numerous environmental factors have been postulated as contributing to the
development of colon cancer. The most important of these appears to be a
contribution from diet, although this is very controversial. Underdeveloped
countries with high fiber diets have less incidence of colon cancer.
Conversely, diets high in fat may impart a greater risk of colon cancer,
as is seen in more industrialized countries. Although animal studies have
suggested a protective benefit to dietary fiber, this has not been demonstrated
in human studies.
Thomas G. Malloy, MD
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SCREENING FOR COLON CANCER
Cancer of the colon is the second most common malignancy affecting men
and women. The natural history of this cancer is that more than half of all
patients will present with an advanced stage of disease and that more than
half of all patients will ultimately succumb to the cancer. To improve these
outcomes, physicians recommend certain screening tests. Screening should
allow recognition of cancer at an earlier, more treatable stage. Also, since
cancer of the colon arises from within pre-existing benign growths called
polyps, recognition and removal of these polyps will interrupt the
polyp-cancer sequence and protect patients from ever developing cancer.
Two simple tests are currently recommended for most patients over the age
of fifty.

Lane A. Kistler,
MD

Fecal occult blood testing consists of preparing several small paper envelopes
with a smear of stool which is tested chemically for the presence of blood.
The test is convenient and simple. If one or more of the specimens reveal
blood, a thorough study of the colon is recommended. The test is done
annually.
Flexible sigmoidoscopy is the examination of the rectum and lower portion
of the colon with a flexible instrument. This test takes ten to twenty minutes
and may be briefly uncomfortable, but it is far more pleasant than the much
maligned rigid-proctoscope which sigmoidoscopy has largely replaced. It is
recommended to be done to patients at intervals of three to five years.
Patients who participate in screening can do so with the knowledge that both
tests have been shown to discover more treatable cancers and to save lives in
the populations studied.
Certain persons have a greater than average risk of developing colon cancer.
Patients with a strong family history of cancer, inflammatory bowel disease
or those who have had a colon polyp removed in the past should discuss
with their doctors the advisability of having even more
thorough testing to screen for colon cancer.
Lane A. Kistler, MD

According to a Professional Education
Publication from the American Cancer
Society, only a small percentage of patients
present with a local (lesion limited to the
mucosa) stage ofcancer. The majority of
patients present to their physician with more
advanced disease following the start of
symptoms such as rectal bleeding, blood in
the stool, or change in bowel habits. The
diagnosis ofcolon cancer at St. Luke’s
appears similar to that described by the
American Cancer Society. In 1927, 62.7%
ofthe patients presented with regional or
distant disease and in 1 992, 69. 1 % of the
patients presented with regional or distant
disease.

General Summary Stage at Diagnosis
Colon Cancer 1 987 vs. 1992
-

LOCAL 27.5

FEGIONAL 42.3
INSITU ai

WKNDM\J 2.9
USTANT 17.6
INSITU a9

WKNON 1.0
LOCAL .8
D$TANT 2&8
FEGIONAL 45.1

1987

1992
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RADIOGRAPFIIC DETECTION OF COLON CANCER
Every year there are 60,000 deaths due to colon cancer in the United States,
making colorectal cancer the second most common cause of death in this
country. Unfortunately, most colon cancers are advanced and incurable by
the time symptoms develop. It is generally believed that the majority of colon
cancers arise from pre-existing adenomatous polyps. Detection and removal
of these polyps has been shown to significantly decrease the incidence of
subsequent colon cancer.

David L. Olson,
MD

The role for radiologic imaging of colon cancer has been primarily directed
at the detection of cancer in the symptomatic patient with barium enema or
for staging of colon cancer with computed tomography. Obviously, it would
be preferable to detect polyps or early cancer while they are still curable. The
traditional method of screening for colon cancer, testing for fecal occult
blood, has proven inaccurate due to its lack of sensitivity and specificity.
Recently, there has been renewed interest in finding a more effective
screening test. Flexible sigmoidoscopy in conjunction with fecal occult blood
testing has received the most support. However, this approach has a major
flaw; it only allows evaluation of half or less of the colon. Forty percent or
more of colon cancers arise in portions of the colon beyond the reach of the
sigmoidoscope. There are two examinations available today that evaluate
the entire colon; colonoscopy and the barium enema. The ability of the
barium enema to detect polyps 1 .0 cm or larger (which is considered the
critical size) or to detect early cancer is comparable to the ability of
colonoscopy. The wider availability, lower complication rate, and lower
cost (compared to colonoscopy) are strong arguments for the use of barium
enema as the preferred method to screen the entire colon.
There are some in the field that have speculated a greater potential impact
from screening for colon cancer than could be realized from screening for
breast cancer. The question of who and when to screen is yet to be
completely resolved, and further study is required. It is clear that individuals
with parents or siblings with colon cancer would definitely benefit from
screening. It appears probable that patients 50 years and older would benefit
from screening every 3 to S years.
David L. Olson, MD
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SURGICAL TREATMENT FOR COLON CANCER
Carcinoma of the col6n has remained a major health hazard
in the United States and most Western Countries. Recent
data reveals that greater than 150,000 people will be afflicted
over one year, with nearly half that number dying of the
disease. Since the turn of the century, surgery has continued
to play the major role in the curative treatment of colon
cancer. Despite its limitations, conventional surgical
treatment accounts for more cures in large bowel cancer than
all other forms of treatment combined. While new
modalities and treatments from the various disciplines may
steadily contribute to an increasing cure rate in future
decades, surgery will remain a mainstay of treatment for this
disease in the foreseeable future.

William R.
Deshur, MD

Patient preparation begins with an evaluation of the patient’s
risk for general anesthesia and abdominal surgery.
Preparation of the colon prior to operation is intended to
reduce the incidence of wound sepsis and of septic intra
abdominal complications.
The principles of operative treatment are based on the
concepts that cancer of the large bowel is rarely spread by
hematogenous routes. It spreads predominantly by
metastasizing first to adjacent lymph nodes and beyond.
Locally invasive tumors invading adjacent organs are also
potentially curable through surgical resection. Based on the
anatomical work of Rouviere we know that the lymph node
architecture of the large bowel mainly follows the arterial
anatomy of the colon. Lymphatic flow is cephalad and in
general, metastases can be found within a given distribution
adjacent to the primary tumor. Downward progression of
the tumor beyond five centimeters from the distal margin, as
well as metastases to secondary lymph node basins can occur
when the proximal primary lymph nodes are already
involved by tumor. Thus an adequate resection not only
involves the tumor with adequate margins but the lymph
node bearing area and the mesentery. Venous ligation prior to
manipulation of the tumor at the level at which mesenteric
arterial vessels are ligated, and ligating the bowel proximally
and distally are concepts that have been used in the
surgical treatment of colon cancer.
In this era of minimally invasive surgery, the role of
laparoscopy and laparoscopy assisted colon resection is just
beginning. How this will add to the armamentarium of the
general surgeon and reduce morbidity in the treatment of
colon cancer is a most exciting prospect for the future.
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VEARS OF SURMVAL

Survival rates published in Cancer Facts & Figures 1987,
reveal a five year survival rate of 53 % for colon cancer
patients with all stages ofdisease. This rate is also reflected
here at St. Luke’s Medical Center (please see graph above)
where a five year survival has been done of patients
diagnosed in 1 987 and followed through 1992.
-

William R. Deshur, MD
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DETECTION AND SURVEILLANCE
Colonoscopy For Colon Cancer
Overall, the mortality rate for colorectal cancer approaches 60%, however, it
has been shown that detection of early lesions can reduce this mortality rate
nearer to 20%. If we are to enhance survival and the quality of life in
patients involved with this disease, earlier detection, and preferably,
prevention of malignant or potentially malignant lesions within the colon
is paramount.

Jeffrey M. Weber,
MD

Unfortunately, early colon cancer and its predecessors, the polypoid tubular
adenoma or tubulovillous adenoma, are often present without the
appearance of any symptoms such as abdominal pain, change in bowel habit
or gross rectal bleeding. It becomes most important then, that if we are to
prevent the appearance of colon cancer or halt its progression early in its
course, we need to identify patients at risk and employ methods of screening
which are the most effective.
Since the etiology of colon cancer is still unknown, this disease cannot be
primarily prevented. Our current strategy focuses on detection of
pre-malignant polyps or early cancer. Those patients with a family history of
first degree relatives (siblings or parent) with polyps or colon cancer ought to
be carefully followed and screened as well as those patients who have already
had colon polyps or colon cancer before. In addition, patients who have had
screening fecal occult blood testing and resultant sigmoidoscopy or barium
enema which have shown polypoid lesions need to have these lesions
removed and examined microscopically. The modality which is employed by
surgeons and gastroenterologists to that end is the colonoscope.
Colonoscopes and other endoscopic instruments which are used to “look
into” the gastrointestinal tract have been in use for many years. The early
instruments such as the rigid gastroscope or proctoscope have, by and large,
been replaced since the mid-1970’s by flexible instruments. Initially, these
instruments employed fiber optic technology allowing the endoscopist to
illuminate and view the gastrointestinal tract. Over the last five years, the
development of video endoscopes has made the visual resolution and comfort
of the procedure both for the physician and patient significantly better.

?Q

6

The colonoscopic experience can be divided into three stages: the
preparation, the procedure, and the post-procedure period.

Preparation:
It’s essential that the gastrointestinal tract be completely clean for adequate
visualization and therapy. Most preparation is done with an oral lavage
accomplished by ingestion of a polyethylene glycol solution just prior to the
procedure. This non-absorbable liquid literally rinses out the gastrointestinal
tract. Alternatively, in patients without a history of renal disease and in
generally good health, Fleet Phospha-Soda can be employed.

Procedure:
Once the patient has been cleansed, the procedure begins. The patient is
placed in the left lateral position, sedated with intravenous tranquilizers and
pain medication and after a digital rectal exam the colonoscope is inserted
and steered through the gastrointestinal tract to its furthest point, the cecum.
Subsequently the colonoscope is slowly withdrawn and examination is done
for polypoid or malignant lesions. Polyps, which often look like mushrooms
with a stalk of variable length and a head, are snared with a wire loop.
Electrocautery is applied and they are removed and cauterized. Small, flat
polyps can be removed with a forceps.

Post-Procedure:

The post-procedure period is primarily concerned with observation for any of
the complications of colonoscopy and polypectomy which include
post-polypectomy bleeding, adverse drug reactions or perforation. These
risks fortunately are very rare but are considerably serious and the patient is
forewarned to watch for any rectal bleeding, abdominal pain, fever, nausea or
vomiting post-procedure.
Recent studies have confirmed what has been suspected for some time, that
removal of small non-malignant adenomatous polyps from the colon does
reduce the risk of later development of colon cancer. Colonoscopy has
become a valuable tool in the prevention and early detection of this disease
which affects almost 150,000 patients in the United States per year.
Identification of patients at risk and removal of significant polyps before they
have evolved into malignancy offers our best hope at controlling and even
reducing the incidence of this disease.
Jeffrey M. Weber, MD
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CHEMOTHERAPY FOR COLON CANCER
Surgery for colon cancer is curative in 50% of patients with resectable
disease. The remaining patients will relapse in the liver, peritoneum or lung
and ultimately die of their disease, having a median survival of 8 months
from the appearance of metastatic disease. The possibility of recurrence can
be predicted by the extent of disease penetration through the bowel wall and
presence of lymph node metastasis. Prognosis is also adversely affected by
obstruction or perforation. Age is not a factor, since those over 70 have an
acceptable morbidity, mortality and long term survival with standard
resections and chemotherapy programs.

Adjuvant Chemotherapy

Ronald D. Hart,
MD

The long term survival rates for patients treated for Duke’s B disease with
surgery alone are 70% to 80%. These patients do not require adjuvant
chemotherapy unless there is associated obstruction or perforation. The
majority of patients with Duke’s C lesions, however, have microscopic
distant metastasis at the time of the surgery and do benefit from adjuvant
chemotherapy programs. The early clinical trials reported an 8 %
improvement in survival with MOF chemotherapy, which includes
Mitomycin, Oncovin and 5-Fluorouracil (5-FU). Subsequent trials of 5-FU
and Levamisole, a biological response modifier, have demonstrated a 12%
improvement in survival from 50% to 63%. Current trials using 5-FU and
Leucovorin are expected to provide even further benefits, based on their
greater effectiveness in patients with advanced metastatic disease. Hepatic
infusions of chemotherapy showed promise in early adjuvant trials but this
has not been confirmed by 3 subsequent trials. There is a high rate of
biliary sclerosis and gastrointestinal complications with this infusion
treatment. Hepatic radiation was evaluated by the GITSG (GI Tumor Study
Group) but did not lead to a decrease in hepatic metastasis or an
improvement in survival.
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Advanced Disease
Some patients present with regionally advanced disease and are at higher risk
for local recurrences. Radiation therapy may be able to improve disease
control in these patients if it is added to effective chemotherapy. This
concept is now being tested in a randomized controlled trial. Ten to twenty
percent of patients with extensive metastatic disease significantly benefit from
treatment with 5-FU used as a single drug. Three trials have shown that
adding Cis-Platin to 5-FU confers no benefit. Adding Leucovorin to 5-FU,
however, leads to a significantly higher response rate. This was recently
confirmed by a meta analysis of 9 clinical trials. This chemotherapy
combination is now being tested in the adjuvant setting to determine its
impact on survival. Current clinical trials are aimed at improving these
results by modulating the effect of 5-FU through the addition of PALA,
Methotrexate or Interferon. All patients with metastatic disease should be
evaluated for participation in these research programs since they incorporate
the most effective treatments available while at the same time answer
research questions of critical importance to all future patients.
Ronald D. Hart, MD

According to a Professional Education
Publication from the American Cancer
Society, surgical treatment has been the
mainstay of therapy for colorectal cancer since
1 902 when the first abdominoperineal resec
tion was performed. Radiation therapy was
first used in the management of colorectal
cancer in 1 91 4 and in recent years has been
accepted as an adjuvant modality. The role of
chemotherapy in treating advanced cases is
currently under study. Combinations of
chemotherapy and immunologic agents have
recently been described as beneficial in
postoperative patients with known positive
lymph nodes. As the bar graphs show,
surgery alone is still the most common
treatment used here at St. Luke’s with
chemotherapy being the second most
common. Studies are underway to prove if
adjuvant therapy may play an important role
in the future survival of colon cancer patients.
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CANCER: THE GENE HUNT CONTINUES
Knowledge of the genetic and biological events involved in colorectal
polyp and tumor formation is progressing rapidly. Numerous molecular
studies support the theory that adenocarcinoma of the colon begins as a
pre-malignant lesion, the adenomatous polyp, and progresses through
multiple genetic alterations into invasive carcinoma.
It has long been noted that some colon cancers appear to have familial
patterns. Familial adenomatous polyposis coli (APC) is a prime example.
It is an autosomal dominantly inherited disease in which numerous benign
colorectal polyps develop, and if left untreated progress uniformally into
invasive cancer. In 1987, the gene responsible for APC was mapped by
cytogenetics and found to occur on chromosome 5. A mutation in this
gene has been found to be responsible for development of the disease.
Other primary genetic changes implicated in the progression from
adenoma to carcinoma include mutations or deletions in the MCC gene
( Chromosome 5Q), the “ras” genes, DCC genes (18Q), and the p53 gene
(17P). Genetic alterations in colorectal tumors include both activation of
oncogenes (ras) positive regulators of cell growth and inactivation of
tumor suppressor genes (DCC, p53).

David Dozer,
MD

-

-

Further progress in the understanding of the genetic alterations
responsible for colorectal cancer will allow earlier diagnosis, cost effective
screening for those high risk individuals, as well as novel therapy aimed at
blocking oncogene activation or possibly restoring suppressor gene
function. There is considerable optimism that preventing colorectal
cancer at the genetic level may be a possibility in the future.

The graphs below present the eight most

Irequent colon cancer histologies in 1987

and 1 992. Adenocarcinoma is by far the
most common histology found for each year.

David Dozer, MD

COLON CANCER HISTOLOGIES 1987

SOLON CANDER HISTOLOGIES 1992
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THE GASTROINTESTINAL CENTER
In 1994, approximate1y 157,000 new cases of colorectal cancer will be
diagnosed with 60,000 related deaths. With the United States identified as a
high-risk country for colorectal cancer, measures for screening and early
detection are under constant investigation.
One of the main objectives of the newly expanded Gastrointestinal
Endoscopy Unit located in the Diagnostic and Treatment Center at St. Luke’s
Medical Center is the detection of precancerous lesions.

L

With the advent of fiberoptic endoscopy, a gastroenterologist is able to
pass a flexible, lighted fiberoptic tube to visualize and biopsy most of the
gastrointestinal tract where cancer develops.

Joseph E.

•1
I.

-

J1r)

Geenen,

MD

Examination of the entire colon can be performed through a procedure
called colonoscopy. Last year, 1,350 colonic examinations were performed
in the Diagnostic and Treatment Center to detect premalignant lesions.
Generally a colonoscopy is scheduled for patients who have abnormal colon
x-rays, anemia, gastrointestinal tract bleeding, personal history or family
history of colon polyps, inflammatory bowel disease, family history of colon
cancer or patients whose stools test positive when screened for the presence
of occult blood.

According to Cancer Facts &
Figures 1992, and the
National Cancer Data
Base 1992:
-

-

Recent studies revealed a 33% reduction in mortality from colorectal cancer
can be achieved by annual fecal occult blood testing with follow-up
colonoscopies scheduled for patients with positive test results. Also statistics
published from the “National Polyp Study” showed that removal of colonic
polyps significantly reduced the incidence of colon cancer by 90%.
Data from several studies currently under investigation suggest that as many
as 70% of all colon cancers are genetically determined. In 2-3 years, blood
tests will enable a physician to determine if a patient is at high risk for
developing colon cancer. Thus, individuals in the high-risk category can be
carefully screened through colonoscopy.
Thus, through screening and the state-of-the-art technology available at the
St. Luke’s Medical Center Gastrointestinal Department, the early detection,
treatment and prevention of colon cancer will continue to show considerable
progress.

The site ofmost colorectal cancers appear to
be shifting higher in the colon; for this
reason, longer, flexible, instruments are
being used, as well as the rigid scope.
The National Cancer Data Base notes a
suggested cephalad migration of colon
cancer. NCDB data from 1 985 and 1988
published in 1 992 reveals an increase in
cancers of the ascending colon and cecum
with a decrease in cancers of the descending
colon and sigmoid. In a comparison to
St. Luke’s Medical Center, a similar increase
is seen in the cecum, ascending colon and
hepatic flexure from 1 987 to 1992.

Joseph E. Geenen, MD

I 987

Transverse Colon
(4 Cases)
Splenic
Flexure
(3 Cases)

Splenic Flexure
(2 Cases)

Hepatic Flexure
(7 Cases)
Descending Colon
(5 Cases)

Descending Colon
(9 Cases)
Ascending
Colon
(9 Cases)

Sigmoid Colon
(39 Cases)

Cecum
(25 Cases)

Sigmoid Colon
(34 Cases)
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SURGICAL ONCOLOGY ROUNDIABLE SERIES

Nanette M.
Johnson, RN, BSN

In 1992, St. Luke’s Medical Center held the Surgical Oncology Roundtable
Series. This roundtable series provided physicians and surgeons the
opportunity to gain information on the most current approaches to treating
head and neck, lung, colon and prostate cancers. Speakers included
Dr. William Panje, Dr. Stephen Hazelrigg, Dr. Victor Fazio, and Dr. Howard
Winfield. One-hour lectures were presented followed with short roundtable
discussions with a panel of experts from St. Luke’s Medical Center.
The topics discussed included the management of advanced head and neck
cancer, the role of thoracoscopy in lung cancer, ileo-anal anastomosis, and
laparoscopic lymph node dissection of obturator nodes for prostate cancer
staging. This series provided physicians and fellow healthcare team members
the opportunity to listen and interact with experts from multidisciplinary
areas.
Nanette M. Johnson, RN, BSN
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MELANOMA VACCINE
Focus of MalcoimMitchell’s Visit
The incidence of malignant melanoma is growing at a rate faster than any
other cancer except lung cancer in women. Surgery remains a successful
treatment of the primary tumor, but disseminated melanoma has been
resistant to standard therapies such as chemotherapy and radiation therapy.
The five year survival rate for patients with distant disease is a dismal
five percent.
The unsatisfactory response to traditional treatments for metastatic disease
has stimulated investigation into other modalities, particularly immunologic
approaches. One such approach utilizing a melanoma vaccine, was the topic
of a presentation given by Malcolm Mitchell, MD, of the University of
Southern California. Dr. Mitchell presented “The Biological Treatment of
Cancer” in June at St. Luke’s Medical Center. His visit here coincided with
the start of St. Luke’s participation in a nationwide Phase III Clinical Trial
comparing the melanoma vaccine Melacine® with conventional
chemotherapy for the treatment of disseminated melanoma. Dr. Mitchell
concentrated his remarks on current studies using a therapeutic vaccine
against melanoma which he developed. This vaccine, known as Melacine® is
a type of active specific immunotherapy which works by activating the
immune response and targeting malignant cells for destruction. A mixture of
lysates of two allogeneic melanoma cell lines is combined with an adjuvant
called DETOX, and is injected intramuscularly once a week. Phase I and II
trials with Melacine® conducted by Dr. Mitchell have shown that the vaccine
is immunogenic, as evidenced by an increased number of cytolytic T
lymphocytes directed against melanoma antigens. Dr. Mitchell stated it is not
completely known which antigens prompt the immune system to attack the
cancer cells, but once isolated, it would be “just a matter of simple chemistry
to create synthetic agents”.

Carol A. Rausch,
RN, OCN

Earlier Phase I and II trials conducted by Dr. Mitchell showed favorable
clinical re,ponses in twenty-four percent of patients. Toxicities from
Melacine were minimal, consisting primarily of soreness at the injection site
and rare flu-like symptoms.
Although current use of this vaccine is in patients with measurable disease,
Dr. Mitchell stated Melacine® may ultimately find its primary indication in
the adjuvant setting.
Studies using this and other immunotherapeutic approaches are being
conducted by the Immunotherapy Program in an effort to find more effective
treatment for this deadly disease.
Carol A. Rausch, RN, OCN
Cancer Research Nurse
Immunotherapy Program
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GLOSSARY
Adenoma: A benign neoplasm of the epithelial tissue in which the tumor cells
form glands or gland-like structures in the stroma; tending to compress rather
than infiltrate or invade adj acent tissue
Adenomatous polyp: A polypoid adenoma that consists of benign neoplastic
tissue derived from glandular epithelium
Adjuvant: A substance which aids another, such as an auxiliary remedy
Allogenic: Pertaining to different gene constitutions within the same species
Analytic Cases: Cases which are first diagnosed and/or given their first course
of treatment at St. Luke’s Medical Center
Barium: A type of contrast, radiopaque medium, used for radiographic study
of the lower intestinal tract
Benign: A term for a tumor that does not normally threaten a person’s life
(that is, a tumor that is not cancerous and does not attack)
Cancer: A tumor that attacks and poses a serious threat to a person’s life
Carcinogenic Agents: Cancer producing substances
Cephalad: In a direction toward the head
Chemotherapy: Treatment with powerful drugs that attack cancer cells
Colon: The part of the large intestine extending from the cecum to the rectum
Colonoscope: An elongated endoscope, usually fiberoptic
Colonoscopy: The visual examination of the inner surface of the colon by
means of a colonoscope
Combined Therapy: Refers to any combination of surgery, radiation,
chemotherapy, hormone therapy or other therapy administered jointly as a
single course of treatment
Cytogenetics: The scientific study of the relationship between chromosomal
aberrations and pathological conditions
Diagnostic Only: Cancer related treatment was not given; this may occur for
many reasons; for example, the patient refused treatment, or the patient’s
general condition is unsatisfactory for treatment
Distant Stage: A neoplasm that has spread to other organs or lymph nodes
from the primary tumor.
Enema: A rectal injection for clearing out the bowel
Endoscope: A device consisting of a tube and optical system for observing the
inside of a hollow organ or cavity
Epidemiology: The study of epidemics and epidemic diseases
First Course of Treatment: The tumor directed treatments started within the
first four months after diagnosis
14

Gastroenterologist: A specialist concerned with the function and disorders of
the stomach and intestines
Hematogenous: Pertaining to anything produced from, derived from or
transported by the blood
Histology: The study of cells and microscopic tissues
Immunology: The science concerned with the phenomena of immunity,
induced sensitivity and allergy
In situ: A tumor classified microscopically as in situ, non-invasive,
pre-invasive, non-infiltrating, intraductal, intraepithelial or intraepidermal
Laparoscopy: An examination of the interior of the abdomen by means of an
instrument that is comparable to an endoscope by means of which the
peritoneal cavity can be inspected
Local Stage: Tumor restricted to the organ of origin, but may be invasive or
infiltrating within the organ of origin
Lymph: A nearly clear fluid collected from tissues around the body and
returned to the blood via the lymphatic system
Lymph Nodes: Small bean-shaped structures scattered along the vessels of the
lymphatic system. The nodes filter bacteria and cancer cells that may travel
through the system
Lysate: A material produced by the destructive process of lysis
Malignant: A term for a tumor that can threaten a person’s life; that is, a
tumor that is cancerous. Malignant has the same meaning as cancerous
Metastasis: The spread of cancer from its original site to distant areas. The
cancer cells are carried to distant sites by blood and lymph
Non-Analytical: Cases which are seen at St. Luke’s Medical Center after the
first course of treatment
Occult Blood: Blood found in the feces, in amounts too small to be seen but
detectable by chemical tests
Oncologist: A physician who specializes in treating cancer
Polyp: A general descriptive term with reference to any mass of tissue that
bulges or projects outward from the normal surface level
Polypoid Lesion: A polyp form, a lesion resembling a polyp in gross features
Radiation Therapy: Treatment with high-energy radiation from x-rays or
other sources of radiation
Regional Stage: A tumor that has extended beyond the limits of the organ of
origin into 1 ) surrounding organs or tissues by direct extension, 2) regional
lymph nodes by metastasis, or 3) a combination of 1 and 2 and appears to
have spread no further

15

GLOSSARY
Recurrence: The return of cancer after a disease-free interval
Sepsis: The presence of various pus-forming and other pathogenic organisms,
or their toxins, in the blood or tissues
Sigmoidoscopy: The inspection, through an endoscope, of the interior of the
sigmoid colon
Stage: A term used to describe the size and extent of spread of the cancer
Staging: Tests conducted to determine the stage of cancer
Surgery: The partial or total removal of the tumor excluding a biopsy
Ulcerative Colitis: A chronic, recurrent ulceration of the colon and rectum,
with rectal bleeding, mucosal abscesses, inflammatory pseudopolyps,
abdominal pain and diarrhea

16
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1992 CANCER ANNUAL REPORT STATISTICS
CancerRegistiy Report
In 1992, 1,460 new patients were accessioned into the St. Luke’s Medical
Center Registry: 1,284 analytic, 1 76 non-analytic. The registry data base
now includes over 20,000 cases ofwhich 5,000 patients are actively being
followed annually. With the assistance ofphysicians, office staff, area
hospitals and fellow Cancer Registries we have maintained a 92% follow-up
rate of these patients. The remaining 2 %, our lost to follow-up patients, are
well within the 1 0% allowed by the American College ofSurgeons. In the
past year, we have again welcomed and appreciated the opportunity to
retrieve over 30 requests and inquiries for our registry data base to be used
for special studies, audits, and research by medical staff, administration and
marketing. We have also participated in Long/Short Term Patient Care
Evaluation Studies on Pancreatic and Prostate Cancer as well as a hospital
based Quality Assurance study ofMultiple Myeloma. The graphs and charts
throughout this 1 992 Cancer Program Report will present a brief overview
of cancer diagnosis and treatment at St. Luke’s Medical Center. Additional
information is available to requestors by directing inquiries to the Cancer
Registry Staffat 649-6720.

Sandy Blixt, R.R.A.
Cancer Registrar
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1992 CANCER ANNUAL REPORT STATISTICS
This primary site distribution presents
breast cancer as the most frequently
diagnosed cancer site in 1 992 followed by
prostate, lung and skin cancer respectively. Skin cancer includes all basal cell and
squamous cell carcinomas as well as
melanomas. Colon cancer continues to be
one of the top five cancer sites diagnosed
and treated here at St. Luke’s Medical
Center. Colon cancer and rectal cancer
are sometimes combined when discussed
but have been listed separately for this site
distribution. More details regarding colon
cancer are available throughout this
annual report or by contacting the
Cancer Registry.
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1 992 NEW CASE DISTRI BUflON BY AGE

This age distribution presents the age
group ofSS to 84 as the largest
percentage of accessioned population at
St. Luke’s Medical Center. These patients
from ages 55 to 84 make up 75% of the
total number of new cases for 1992.
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1992 CANCER ANNUAL REPORT STATISTICS
Number of Cases

Percent

In situ

72

4.9%

Local

675

46.2%

Regional

372

25.5%

Distant

277

19.0%

64

4.4%

1 992 GENERAL SUMMARY STAGE
FOR ALL SITES
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1992 General Summary Stage
For Top 5 Sites

Number of Cases

Percent

Insitu

21

8.5%

Local

130

52.8%

Regional

82

33.4%

Distant

12

4.9%

Unknown

1

.4%

BREAST (246 patients)
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1992 CANCER ANNUAL REPORT STATISTICS
Number of Cases

Percent

In situ

0

(\ 0/
U /0

Local

134

68.7%

Regional

36

18.5%

Distant

22

11.3%

3

1.5%

PROSTATE (195 paLients)

Unknown

195
11.3
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I
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LUNG (186 patients)

Number of Cases

Percent

In situ

0

n 0/
U /0

Local

31

16.7%

Regional

70

37.6%

Distant

80

43.0%

Unknown

S

2.7%
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Nuffiber of Cases

Percent

Insitu

12

6.7%

Local

157

88.2%

Regional

5

2.8%

Distant

1

.6%

Unknown

3

1.7%

SKIN (178 patients)

LOCL 88.2—GCNL 2.8

L
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COLON (97 patients)
Number of Cases

Percent

In situ

3

3.1%

Local

26

26.8%

Regional

41

42.3%

Distant

26

26.8%

1

1.0%

Unknown
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PRESENTATIONS AND INSTRUCTIONAL SESSIONS
Nursing
“Implementing a Case Management Nursing Model in the Ambulatory
Oncology Clinic”, Myrtle M. Harlson, RN, OCN, Vince Lombardi Cancer
Clinic
“Hematopoietic Growth Factor-Primed Peripheral Stem Cell Collection for
Use in Patients with Solid Tumors following High Dose
Chemotherapy/Radiation Therapy”, Angela D. Klimaszewski, MSN, RN,
OCN, Cancer Research Coordinator
“Strategies for Obtaining Third-Party Reimbursement for Investigational
ABMT”, Angela D. Klimaszewski, MSN, RN, OCN, Cancer Research
Coordinator
Clinical Trials: The Role of the Oncology Nurse in the Community Hospital
Setting, Carol A. Rausch, BSN, RN, OCN, Research Nurse Specialist,
Immunotherapy
“Landscape Architecture for Oncology Nurses: Redesigning Professional
Environment”, Barbara Ritter, BSN, RN, OCN, Linda R. Burnworth, RN,
MS, OCN, Columbus, OH
Cancer Rehabilitation: Utilizing Existing Services to Enhance Your Cancer
Program”, Barbara Ritter, BSN, RN, OCN
“

An Innovative Continuing Education Conference Attendance and
Reimbursement Application Package for Oncology Units, Barbara Ritter,
BSN, RN, OCN
“Nursing Care of Patients Undergoing Autologous Bone Marrow Transplant
for Breast Cancer: Comparison of Two Protocols”, Pamela Schroeder, BSN,
RN, OCN
“Increasing Independence in Bone Marrow Transplant Patients Through
Contracting”, Pamela Schroeder, BSN, RN, OCN
Orientation Evaluation Form Using Charting by Exception, Peggy Todryk,
RN, Oncology Unit

SI. LUKE’S CANCER CONFERENCES
Tumor Board Conference
Conferences were held on the first, second and fourth Mondays of every month
at noon. They were patient oriented, multi-disciplinary cancer conferences
with an average attendance of 45. For more information or any questions,
please call 649-6720.

Head and Neck Tumor Conference
Conferences were held on the third Monday of every month at noon. They
were held to discuss selected difficult head and neck tumors from a
multi-disciplinary approach. For more information or any questions, please
call 649-3900.

Security Bank Cancer Lectureship Series 1992
April 23, 1992

Cushing’s Syndrome and the Adrenal Neoplasm
D. Lynn Loriaux, MD.
University of Oregon Health Sciences

June 10, 1992

The Biological Treatment of Cancer
Malcolm S. Mitchell, MD.
University of Southern California Cancer Center

September 17, 1992

Helper T-Cell Subsets and their Regulation of
Immune Response
Susan Swain, Ph.D.
University of California San Diego
-

November 12, 1992

Immunotropins in Cancer Therapy
Ellen Vitetta, Ph.D.
University of Texas Southwestern Medical Center

St LUKE’S CANCER CONFERENCES
Surgical Oncology Roundtable Series
May 12, 1992

Contemporary Management of Advanced Head
and Neck Cancer
William R. Panje, MD.
Chairman, Department of Otolaryngology/Head
and Neck Surgery
University of Chicago
Chicago, IL

June 16, 1992

The Role of Thoracoscopy in Lung Cancer
Stephen R. Hazelrigg, MD.
Cardiothoracic Surgery
St. Luke’s Medical Center
Milwaukee, WI

July 7, 1992

fleo-Anal Anastomosis
Victor W. Faizio, MD., F.R.A.C.S.,
F.A.C.S.
Chairman
Department of Colorectal Surgery
The Cleveland Clinic Foundation
Cleveland, OH

September 15, 1992

Laparoscopic Lymph Node Dissection of Obturator
Lymph Nodes For Prostate Cancer Staging
Howard N. Winfield, MD.
Associate Professor
Department of Urology
University oflowa Hospital and Clinics
Iowa City, IA

COMMUNiTY EDUCATION
Vince Lombardi Cancer Clinic Presents:
1992 Community Education and Screening Series
J anuary 23, 1992

“Prostate Disease: What You Need To Know”
Presented by:
Howard Lewis, MD., Radiation Oncologist
Barry Usow, MD., Urologist

February 20, 1992

“Breast Cancer Update”
Presented by:
David Czarnecki, MD., Radiologist
Paul Loewenstein, MD., Reconstructive Surgeon
Wendy Mikkelson, MD., Surgeon
Marcia Richards, MD., Radiation Oncologist
Robert Taylor, MD., Medical Oncologist

March 19, 1992

“Colon Cancer: Prevention, Detection And
Treatment”
Presented by:
William Deshur, MD., Surgeon
Ajit Divgi, MD., Medical Oncologist
Jan Avakian-Kopatich, RN, Enterostomal Therapist
Mitchell Pincus, MD., Radiation Oncologist

April 21, 1992

“Skin Cancer And Melanoma: Rays Of Hope”
Presented by:
J ames Bruckman, MD., Radiation Oncologist
John P. Hanson, MD., Medical Oncologist
Kathy Stokes, MD., Dermatologist

May 6, 1992

“Ovarian Cancer: Are You At Risk?”
Presented by:
Ronald Hart, MD., Medical Oncologist
Julie O’Reilly, MD., Obstetrician/Gynecologist
William Pao, MD., Radiation Oncologist
Kerry Twite, RN., Clinical Nurse
Specialist-Oncology

J une 4, 1992

“Cervical Cancer And The Older Woman”
Presented by:
Ajit Divgi, MD., Medical Oncologist
Julie O’Reilly, MD., Obstetrician/gynecologist
James Taylor, MD., Radiation Oncologist

